Clinical Trials Concentrates DEA THC 
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
Veriheal
AUGUST 31, 2020
Choosing only 10 winners for the $10,000 in scholarships among the strong applications we received from multiple disciplines and concentrations in higher education—from students of all backgrounds and interests—was extremely difficult. Bonaventure University and George Washington University School of Medicine. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 4, 2021
With Delta 8, one is not going to have an anxious or paranoia episode as can be common for newcomers to marijuana forms of cannabis – especially with high concentration of THC that is readily available today. Delta 8-THC is a psychoactive cannabinoid, just like Delta 9-THC, and legislators should regulate it as such.
Cannabis Law Report
JANUARY 11, 2019
Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.
The Cannigma
MAY 6, 2021
Delta-8-THC, a close relative of the more famous delta-9-THC, acts in many of the same ways producing a similar high and even some of the same therapeutic effects. What is delta-8-THC. Along with delta-9-THC, delta-8 is one of the few cannabinoids considered to be intoxicating. (El Sound too good to be true?
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.
SpeedWeed
DECEMBER 28, 2018
Marinol (synthetic THC) has been available by prescription since 1986, and other synthetic cannabinoid drugs are in the works, but Epidiolex is the first plant-derived pharmaceutical to reach the US market. There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval.
Expert insights. Personalized for you.
133 
Let's personalize your content